Merck’s KEYTRUDA-Based Regimen Achieves Major Milestone in Phase 3 KEYNOTE-B96 Trial for Platinum-Resistant Ovarian Cancer Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada, announced a significant advancement in the treatment of platinum-resistant recurrent…
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into a definitive agreement to acquire efimosfermin alfa, a potential best-in-class…
FDA Approves Merck’s WELIREG® (belzutifan) for Advanced Pheochromocytoma and Paraganglioma in Patients 12 Years and Older, Marking a New Era in Treatment of Rare Neuroendocrine Tumors Merck, known as MSD outside of the United States and Canada, has announced a…
Novo Nordisk and Septerna Forge $2.2 Billion Global Alliance to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases In a significant expansion of its research and development pipeline, Novo Nordisk has entered into a landmark global collaboration and…
Sarepta’s ELEVIDYS Gene Therapy Gains Landmark Approval in Japan for Duchenne Muscular Dystrophy Sarepta Therapeutics, a biotechnology leader in precision genetic medicine for rare diseases, has announced a significant regulatory milestone: the Japanese Ministry of Health, Labour and Welfare (MHLW)…
UCB Highlights Robust Data on Generalized Myasthenia Gravis Therapies at 15th MGFA International Conference, Reinforcing Commitment to Patient-Centered Innovation UCB,a global biopharmaceutical leader specializing in immunology and neurology, has announced the presentation of a comprehensive suite of data from its…
Aetna, National Alliance for Care at Home, and MissionCare Collective Partner to Strengthen the Direct Care Workforce in Illinois, Louisiana, and North Carolina In a bold and strategic move to address critical workforce shortages in the home health care sector,…
Merck to Unveil Broad Range of Clinical Advances Across 25+ Cancer Types at ASCO 2025 Merck (NYSE: MRK), known as MSD outside the United States and Canada, is set to make a major impact at the upcoming 2025 American Society…
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful completion of a €132 million ($142 million USD equivalent) Series…
InnoCare’s Mesutoclax Granted Breakthrough Therapy Designation by China’s NMPA In a landmark development for China’s oncology therapeutics landscape, InnoCare Pharma Limited (HKEX: 09969; SSE: 688428), a biopharmaceutical company recognized for its focused innovation in cancer and autoimmune disease treatment, announced…
Hansoh Pharma’s Ameile Gains Approval for New Indication in Early-Stage EGFR-Mutant NSCLC Hansoh Pharmaceutical Group Co., Ltd (03692.HK), hereafter referred to as Hansoh Pharma, announced that its innovative product Ameile (almonertinib mesylate tablets) has received approval in China for a…
Johnson & Johnson (NYSE: JNJ) today announced promising new results from the Phase 3 ICONIC-TOTAL study evaluating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide designed to selectively block the IL-23 receptor. The study included adults and adolescents (12 years…